Jiaying Liu, Randall Toy, Casey Vantucci, Pallab Pradhan, Zijian Zhang, Katie M Kuo, Kelsey P Kubelick, Da Huo, Jianguo Wen, Jinhwan Kim, Zhiheng Lyu, Simran Dhal, Alexandra Atalis, Shohini K Ghosh-Choudhary, Emily J Devereaux, James C Gumbart, Younan Xia, Stanislav Y Emelianov, Nick J Willett, Krishnendu Roy
Monoclonal antibodies (mAb) have had a transformative impact on treating cancers and immune disorders. However, their use is limited by high development time and monetary cost, manufacturing complexities, suboptimal pharmacokinetics, and availability of disease-specific targets. To address some of these challenges, we developed an entirely synthetic, multivalent, Janus nanotherapeutic platform, called Synthetic Nanoparticle Antibodies (SNAbs). SNAbs, with phage-display-identified cell-targeting ligands on one "face" and Fc-mimicking ligands on the opposite "face", were synthesized using a custom, multistep, solid-phase chemistry method...
January 4, 2021: Nano Letters